Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

DWTX

Dogwood Therapeutics Inc

Dec 13 • 04:00PM ET

2.36

Dollar change -0.05
Percentage change -2.07	%

Healthcare • Biotechnology • USA • NASD

Peers: AZN RARE NBIX IRWD XENE ANIP SAGE PRTA ATNM RDHL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.87	Insider Own	11.73%	Shs Outstand	1.33M	Perf Week	-0.42%
Market Cap	3.07M	Forward P/E	-	EPS next Y	-7.28	Insider Trans	0.00%	Shs Float	1.18M	Perf Month	-20.54%
Income	-4.68M	PEG	-	EPS next Q	-1.36	Inst Own	3.20%	Short Float	2.79%	Perf Quarter	-51.93%
Sales	0.00M	P/S	-	EPS this Y	19.43%	Inst Trans	14.43%	Short Ratio	0.31	Perf Half Y	-60.37%
Book/sh	2.82	P/B	0.84	EPS next Y	-28.99%	ROA	-105.77%	Short Interest	0.03M	Perf Year	-85.91%
Cash/sh	2.32	P/C	1.02	EPS next 5Y	-	ROE	-119.56%	52W Range	1.62 - 23.50	Perf YTD	-83.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.02%	ROI	-149.22%	52W High	-89.96%	Beta	1.33
Dividend TTM	-	Quick Ratio	7.27	Sales past 5Y	0.00%	Gross Margin	-	52W Low	45.68%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	7.27	EPS Y/Y TTM	57.50%	Oper. Margin	-	RSI (14)	40.10	Volatility	10.81% 18.96%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	25.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	41.43%	Payout	-	Rel Volume	0.05	Prev Close	2.41
Sales Surprise	-	EPS Surprise	-74.22%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	107.22K	Price	2.36
SMA20	-6.24%	SMA50	-31.34%	SMA200	-62.11%	Trades		Volume	4,931	Change	-2.07%

Nov-18-24 08:45AM	Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study (GlobeNewswire) -37.71%
Nov-08-24 02:35AM	Q3 2024 Dogwood Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
Nov-07-24 07:05AM	Dogwood Therapeutics Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 09:15AM	Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 (GlobeNewswire)
09:15AM	Loading…
Oct-30-24 09:15AM	Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.73%
Oct-08-24 08:29AM	Virios Therapeutics Transforms into Dogwood Therapeutics (TipRanks) +12.40%
Oct-07-24 07:05AM	Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: DWTX ) (GlobeNewswire) -18.50%
Aug-08-24 09:15AM	Virios Therapeutics Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 09:41AM	Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jul-23-24 09:15AM	Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center (GlobeNewswire) +6.70%
May-22-24 01:30PM	Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) +10.83%
May-20-24 02:19PM	Top Midday Decliners (MT Newswires) -43.94%
10:25AM	Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain? (InvestorPlace)
09:20AM	Why Is Virios Therapeutics (VIRI) Stock Down 44% Today? (InvestorPlace)
07:36AM	Loading…
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
03:54AM	Virios Therapeutics Prices $1.7 Million Common Stock Offering (MT Newswires)
May-19-24 08:53PM	Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire)
May-17-24 04:10PM	Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) -8.96% -43.94%
May-13-24 10:49AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:45AM	Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -13.15%
May-02-24 09:15AM	Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 (GlobeNewswire)
Mar-26-24 09:15AM	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID (GlobeNewswire) -8.45%
Feb-29-24 09:15AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 09:15AM	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones (GlobeNewswire)
Jan-22-24 09:00AM	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID (GlobeNewswire) -40.27%
Jan-02-24 07:05AM	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID (GlobeNewswire)
Nov-14-23 09:55AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:05AM	Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -10.54%
Nov-06-23 07:05AM	Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 (GlobeNewswire) +6.40%
07:05AM	Loading…
Oct-12-23 07:05AM	Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023 (GlobeNewswire)
Sep-18-23 07:05AM	Virios Therapeutics Announces Termination of At-The-Market Sales Agreement (GlobeNewswire)
Sep-12-23 07:05AM	Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023 (GlobeNewswire)
Aug-15-23 07:48AM	VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024 (Zacks)
Aug-14-23 07:05AM	Virios Therapeutics Announces Halt to At-The-Market Offering Sales (GlobeNewswire) +18.52%
Aug-12-23 09:40AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 07:05AM	Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -31.21%
Aug-09-23 07:05AM	Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia (GlobeNewswire) -7.10%
Aug-03-23 04:05PM	Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-24-23 08:40AM	VIRI: Encouraging Results for IMC-2 in Long COVID (Zacks)
Jul-17-23 02:20PM	Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People (Benzinga) -20.25%
07:05AM	Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study (GlobeNewswire)
May-25-23 04:05PM	Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -9.70% +19.01%
May-16-23 10:26AM	VIRI: Ready to Move IMC-1 Into Phase 3 Program (Zacks Small Cap Research)
May-15-23 07:05AM	Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia (GlobeNewswire)
May-11-23 07:49AM	VIRI Stock Earnings: Virios Beats EPS Estimates (InvestorPlace) -6.96%
07:39AM	We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate (Simply Wall St.)
07:05AM	Virios Therapeutics Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 07:05AM	Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +9.75%
Apr-25-23 01:07PM	Virios Therapeutics Shares Almost Double In Trading Session - Here's Why (Benzinga) +55.13%
Apr-24-23 04:15PM	Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia (GlobeNewswire) -8.03%
Mar-16-23 07:10AM	VIRI: Anticipating Update on IMC-1 Following End-of-Phase 2 Meeting with FDA (Zacks Small Cap Research)
Mar-14-23 07:05AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-07-23 07:05AM	Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 (GlobeNewswire) -14.32%
Feb-13-23 07:05AM	Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023 (GlobeNewswire)
Jan-05-23 07:00AM	Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program (GlobeNewswire) +10.93%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 07:05AM	Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase (Business Wire)
Nov-22-22 06:15AM	VIRI: Ready to Approach FDA with Phase 3 Plans (Zacks Small Cap Research)
Nov-14-22 07:05AM	Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) -10.50%
Nov-03-22 07:05AM	Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 (Business Wire)
Sep-23-22 07:27AM	VIRI: Raises Gross Proceeds of $5 Million Through Underwritten Public Offering (Zacks Small Cap Research) -5.93%
Sep-22-22 04:15PM	Virios Therapeutics, Inc. Announces Closing of Public Offering (Business Wire) -5.21%
Sep-19-22 10:04PM	Virios Therapeutics, Inc. Announces Pricing of Public Offering (Business Wire) -77.19% -75.50%
04:05PM	Virios Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
11:20AM	VIRI: FORTRESS Trial Does Not Meet Primary Efficacy Endpoint (Zacks Small Cap Research)
09:33AM	Virios Therapeutics Shares Tank After Failing Fibromyalgia Study (Benzinga)
08:22AM	Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate (MarketWatch)
07:05AM	Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia (Business Wire)
Sep-16-22 09:30AM	New to The Street TV / Newsmax TV Announces its Eight Interviews on This Week's TV Broadcast, Episode #386, September 18, 2022, 10-11 AM ET (GlobeNewswire) +13.02%
Sep-12-22 09:30AM	New to The Street TV Announces Four Corporate Interviews on its 384th TV Show, Airing on the Fox Business Network, Tonight, Monday, September 12, 2022, at 10:30 PM PT (GlobeNewswire) +7.69%
Sep-05-22 06:47AM	Here's Why Virios Therapeutics (NASDAQ:VIRI) Must Use Its Cash Wisely (Simply Wall St.)
Aug-15-22 07:24AM	VIRI: Topline Results for FORTRESS Trial Expected in September 2022 (Zacks Small Cap Research)
07:05AM	Virios Therapeutics Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial (Business Wire)
Aug-11-22 07:05AM	Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) +8.45%
Aug-10-22 04:01PM	Virios Therapeutics, Inc. to Present at Investor Summit Groups Q3 Virtual Conference (Business Wire)
Aug-08-22 08:30AM	Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans (Newsfile)
Aug-04-22 07:05AM	Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022 (Business Wire)
Jul-26-22 08:30AM	Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment (Newsfile)
Jul-19-22 08:30AM	Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results (Newsfile)
Jun-01-22 07:05AM	Virios Therapeutics Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia (Business Wire)
May-17-22 12:05PM	VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022 (Zacks Small Cap Research) +17.05%
May-12-22 07:05AM	Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) +5.44%
May-05-22 07:05AM	Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (Business Wire) -5.54%
Apr-28-22 07:05AM	Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for Fibromyalgia (Business Wire)
Mar-28-22 07:10PM	We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate (Simply Wall St.) -11.62%
Mar-21-22 06:25AM	VIRI: Testing Combination Antiviral Therapy to Treat Long COVID (Zacks Small Cap Research)
Mar-17-22 07:05AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (Business Wire) +8.01%
Mar-10-22 07:05AM	Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022 (Business Wire)
Mar-08-22 04:05PM	Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022 (Business Wire) +6.60%
Feb-28-22 07:05AM	Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID (Business Wire)
Feb-01-22 03:00AM	A Fireside Chat with Greg Duncan - CEO of Virios Therapeutics (Zacks Small Cap Research)
Jan-26-22 04:30PM	RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28 (ACCESSWIRE)
Jan-04-22 04:05PM	Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference (Business Wire)
Dec-01-21 07:05AM	Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia (Business Wire) -6.97%
Nov-15-21 07:34AM	VIRI: Filed IND for IMC-1 in Irritable Bowel Syndrome (Zacks Small Cap Research)
Nov-11-21 07:05AM	Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Nov-04-21 07:05AM	Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021 (Business Wire) -6.68%
Sep-28-21 03:33PM	Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation (Simply Wall St.)
Sep-08-21 07:05AM	Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination (Business Wire)

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DWTX

Dogwood Therapeutics Inc

Upgrade your FINVIZ experience